Join to View Full Profile
300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000
Dr. Mikkilineni is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am an oncologist who focuses on conducting cellular therapy clinical trials for multiple myeloma.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2016 - 2019
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2013 - 2016
Tulane University School of MedicineClass of 2013
Certifications & Licensure
CA State Medical License 2022 - 2026
MD State Medical License 2016 - 2023
PA State Medical License 2013 - 2016
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CCF-ASCO Young Investigator Award ASCO; Funded by NIH, 2019
- Clinical Training Research Institute American Society of Hematology, 2018
Clinical Trials
- Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation Start of enrollment: 2010 Aug 04
- Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies Start of enrollment: 2015 Sep 24
- T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies Start of enrollment: 2016 Jan 21
- Join now to see all
Publications & Presentations
PubMed
- Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy.Snegha Ananth, Nancy Eunice Torres, Bita Sahaf, Lekha Mikkilineni, Sebastian Fernandez-Pol
Blood Advances. 2025-08-12 - Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy.Binod Dhakal, Othman Salim Akhtar, David Fandrei, Alexandria Jensen, Rahul Banerjee
Blood. 2025-08-01 - A 17-Year Experience of a Large Dedicated Fellowship in Blood and Marrow Transplantation and Cellular Therapy: A Blueprint for Modern Day Training Program.Sushma Bharadwaj, Robert Lowsky, Lekha Mikkilineni, Melody Smith, Wen-Kai Weng
Journal of Cancer Education. 2025-08-01
Lectures
- Infectious Complications Associated with CAR T-Cell Therapy61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
